-+ 0.00%
-+ 0.00%
-+ 0.00%

Forte Biosciences Q2 FY26 net loss widens 107.4% to $23.33 million

PUBT·08/12/2026 20:04:13
Listen to the news
Forte Biosciences Q2 FY26 net loss widens 107.4% to $23.33 million
  • Forte Biosciences posted a wider net loss of USD 23.33 million for Q2 2026, up from USD 11.25 million a year earlier.
  • Operating expenses more than doubled to USD 24.6 million, led by R&D spending rising to USD 22.34 million from USD 8.62 million.
  • R&D climbed due to USD 12 million higher manufacturing and clinical costs for FB102 trials, partly offset by lower G&A at USD 2.27 million.
  • Cash, cash equivalents and short-term investments totaled USD 198.5 million as of June 30, 2026; a USD 172.5 million equity offering closed in April.
  • Entered a merger agreement with argenx for a USD 77 per share cash tender offer; the offer began Aug. 6, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forte Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-346787), on August 12, 2026, and is solely responsible for the information contained therein.